Market Analysis and Insights: Global Needle-Free Drug Delivery Systems Market
Due to the COVID-19 pandemic, the global Needle-Free Drug Delivery Systems market size is estimated to be worth US$ 10560 million in 2022 and is forecast to a readjusted size of US$ 16720 million by 2028 with a CAGR of 8.0% during the review period. Fully considering the economic change by this health crisis, Jet-Based accounting for % of the Needle-Free Drug Delivery Systems global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Needle-Free Drug Delivery Systems market size is valued at US$ million in 2021, while the US and Europe Needle-Free Drug Delivery Systems are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Needle-Free Drug Delivery Systems landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Needle-Free Drug Delivery Systems include Antares Pharma, Pharmajet, Optinose, Valeritas, Crossject, Injex Pharma, 3M Pharmaceuticals, Becton Dickinson (BD) and MedImmune, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Needle-Free Drug Delivery Systems Scope and Segment
Needle-Free Drug Delivery Systems market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Needle-Free Drug Delivery Systems market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Jet-Based
Spring-Based
Laser-Based
Segment by Application
Hospital
Clinic
Others
By Company
Antares Pharma
Pharmajet
Optinose
Valeritas
Crossject
Injex Pharma
3M Pharmaceuticals
Becton Dickinson (BD)
MedImmune
Mystic Pharmaceuticals
Zogenix
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE